Development of surface-functionalised nanoparticles for FGF2 receptor-based solid tumour targeting

Journal of Microencapsulation

Volumn 29, Issue 1, 2012, Pages 95-102

  Jain, Amit ^a   Gulbake, Arvind ^a   Jain, Ashish ^a   Shilpi, Satish ^a   Hurkat, Pooja ^a   Jain, Aviral ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Cisplatin; FGF2 receptor; Gelatin nanoparticles; Heparin; Tumour targeting

Indexed keywords

CISPLATIN; FIBROBLAST GROWTH FACTOR RECEPTOR; GELATIN; GELATIN NANOPARTICLE; HEPARIN; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DESOLVATION; DRUG DISTRIBUTION; DRUG RELEASE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN TARGETING; SOLID TUMOR; SOLVATION; SURFACE CHARGE; SURFACE PROPERTY;

CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; RECEPTORS, FIBROBLAST GROWTH FACTOR; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84855878356     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.635219     Document Type: Article

References (25)

1. Azarmi S, Huang Y, Chen H, McQuarrie S, Abrams D, Roa W, Finlay WH, Miller GG, Löbenberg R. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B oste-osarcoma cancer cells. J Pharm Pharm Sci, 2006;9:124-32.
2. Borkovec M. 2002. Measuring particle size by light scattering. In: Holmberg K, editor. Handbook of applied surface and colloid chemistry. New York: John Wiley & Sons, pp. 357-70.
3. Cascon MG, Lazzeri L, Carmignani C, Zhu Z. Gelatin nanoparticles produced by a simple w/o emulsion as a drug delivery of methotrexate. J Mater Sci Mater Med, 2002;13:523-6. (Pubitemid 34454486)
4. Chung Y, Tae G, Yuk SH. A facile method to prepare heparin-functiona- lized nanoparticles for controlled release of growth factors. Biomaterials, 2006;27:2621-6. (Pubitemid 43113286)
5. Coester CJ, Langer K, Briesen HV, Kreuter J. Gelatin nanoparticles by two step desolvation: A new preparation method, surface modifications and cell uptake. J Microencapsulation, 2000;17:187-93. (Pubitemid 30135796)
6. Dickson C, Spencer-Dene B, Dillon C, Fantl V. Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors. Breast Cancer Res, 2000;2:191-6. (Pubitemid 32223584)
7. Elbert S, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release, 2000;65:389-402. (Pubitemid 30122941)
8. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv Drug Deliv Rev, 2001;47:113-31. (Pubitemid 32209236)
9. Konishi M, Tabatab Y, Kariya M, Hosseinkhani H, Suzuki A, Fukuhara K, Mandai M, Takakura K, Fujii S. In vivo anti-tumor effect of dual release of Cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release, 2005;103:7-19. (Pubitemid 40248557)
10. Konishi M, Tabata Y, Kariya M, Suzuki A, Mandai M, Nanbu K, Takakura K, Fujii S. In vivo anti-tumor effect through the controlled release of Cisplatin from biodegradable gelatin hydrogel. J Control Release, 2003;92:301-13. (Pubitemid 38366153)
11. Leo E, Cameroni R, Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J Pharm, 1999;180:23-30. (Pubitemid 29131439)
12. Leo E, Vandelli MA, Cameroni R, Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: Involvement of the drug in the cross-linking process. Int J Pharm, 1997;155:75-82. (Pubitemid 27368124)
13. Moffat AC, Osselton MD, Widdop B, Watts J. 2005. Clarke's analysis of drugs and poisons. London: Pharmaceutical Press.
14. Narayami R, Rao KP. Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres. J Microencapsul, 1994;11:69-77.
15. Oppenheim RC, Stewart NF. The manufacture and tumor cell uptake of nanoparticles labelled with fluoroscein isothiocyanate. Drug Dev Ind Pharm, 1979;5:583-91.
16. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly (lactide) vitamin E TPGS nanoparticles. Biomaterials, 2008;29:2663-72.
17. Park K, Kim JH, Nam YS, Lee S, Nam HY, Kim K, Park JH, Kim IS, Choi K, Kim SY, et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release, 2007;122:305-14. (Pubitemid 47404663)
18. Rosenberg B. Platinum complexes for the treatment of cancer. Interdiscipl Sci Rev, 1978;3:134-47.
19. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release, 2003;92:49-67. (Pubitemid 37130121)
20. Shenoy DB, Amiji MM. Poly (ethylene oxide) modified poly (caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm, 2005;293:261-70. (Pubitemid 40381098)
21. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nano-particles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev, 1995;17:31-48.
22. Tabata Y, Ikada Y. Synthesis of gelatin microspheres containing interferon. Pharm Res, 1994;6:422-7.
23. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J, 2007;9:128-47.
24. Veis A. 1964. The macromolecular chemistry of gelatin. New York: Academic Press.
25. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterization of protein nanoparticles. Int J Pharm, 2000;194:91-102.